GLP1R and medullary thyroid gland carcinoma: found an increased risk for developing medullary thyroid cancer in patients using GLP‐1 agonists for 1–3 years, with an adjusted HR of 1.78 (95% CI 1.04–3.05) and an adjusted HR of 1.58 (95% CI 1.27–1.95) for all thyroid cancers [28].